

Standard Control Formulary™

July 2024 Updates

Removals	Add-Backs
5	4

Removals

Drug Class	Removed Product(s)	Formulary Options
Anti-Infectives, Antivirals*	XERESE	acyclovir capsule, acyclovir tablet, valacyclovir
Cardiovascular, Antilipemics, Omega-3 Fatty Acids*	VASCEPA**	icosapent ethyl, omega-3 acid ethyl esters
Endocrine and Metabolic, Contraceptives*	NUVARING**	ethinyl estradiol-etonogestrel, ANNOVERA
Endocrine and Metabolic, Gaucher Disease*	VPRIV	CERDELGA, CEREZYME
Pain, Opioid Analgesics*	tramadol tablet 100mg [†]	tramadol (except tramadol tablet 100 mg), tramadol ext-rel tablet

Add-Backs

Drug Class	Product(s) Added
Antineoplastic Agents, Kinase Inhibitors*	XALKORI ORAL PELLETS (non-preferred)
Cardiovascular, Antilipemics, Omega-3 Fatty Acids*	icosapent ethyl
Endocrine and Metabolic, Contraceptives*	EluRyng, EnilloRing, ethinyl estradiol-etonogestrel, Haloette
Gastrointestinal, Miscellaneous*	MOVANTIK

New to Market Updates

Drug Class	Product(s) Added
Anti-Infectives, Antiretroviral Combination Agents*	CABENUVA
Endocrine and Metabolic, Enzyme Replacements*	ELFABRIO

*Class has existing formulary exclusions **Multi-source Brand Product † Tramadol 100mg will be moving from an NDC-specific exclusion to a drug-specific exclusion effective July 1, 2024. This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates. Information listed is current as of April 30, 2024 and subject to change.